So far it is well tolerated, and despite the fact that it has been on the market for a short time, the patients to whom it has been prescribed have had a favorable evolution.
According to the National Urology Group, this illness has affected, on average, between 8 and 12 percent of adults and one percent of the pediatric population in the last decade.
In view of its prevalence in the country, it was necessary to reverse the import matrix of potassium citrate tablets (Acalka) with the domestic production of a similar drug that would reduce the purchase cost.
It is an oral solution for both adult patients and children at an early age, since the latter could not consume the Acalka tablet because of its size, nor could it be fractionated, because it caused adverse gastrointestinal reactions.
According to Granma newspaper, it is important to socialize its benefits among specialists who treat renal calculus as well as to better organize its distribution at the pharmacy level.
“Producing and commercializing this drug and not having to import it means a very positive economic impact for the country,” the newspaper emphasizes.
It is not used in all patients with renal stones, “as there are exclusion criteria, such as having severe renal insufficiency or an active urinary tract infection, so its use always requires a medical prescription”.